ETFdb Logo
ETFdb Logo
ETFdb Logo
ETFdb Logo
  • Channels
    • Active ETF
    • Alternatives
    • Beyond Basic Beta
    • China Insights
    • Climate Insights
    • Commodities
    • Core Strategies
    • Crypto
    • Disruptive Technology
    • Dividend
    • Dual Impact
    • Emerging Markets
    • Energy Infrastructure
    • Entrepreneur ETF
    • Equity ETF
    • ESG
    • ETF Building Blocks
    • ETF Education
    • ETF Strategist
    • Fixed Income
    • Future ETFs
    • Gold & Silver Investing
    • Innovative ETFs
    • Institutional Income Strategies
    • Leveraged & Inverse
    • Managed Futures
    • Modern Alpha
    • Multi-Asset
    • Multi-Factor
    • Nasdaq Investment Intelligence
    • Portfolio Strategies
    • Retirement Income
    • Smart Beta
    • Thematic Investing
    • Volatility Resource
  • Database
  • Tools
    • ETF Screener
    • ETF Country Exposure Tool
    • ETF Sector Tracker Tool
    • ETF Database Categories
    • Head-To-Head ETF Comparison Tool
    • ETF Stock Exposure Tool
    • ETF Issuer Fund Flows
    • Indexes
    • Mutual Fund To ETF Converter
    • ETF Data for Journalists
    • ETF Nerds
  • Research
    • First Bitcoin ETF
    • ETF Education
    • Equity Investing
    • Dividend ETFs
    • Leveraged ETFs
    • Inverse ETFs
    • Top ETF Sectors
    • Top ETF Issuers
    • Top ETF Industries
  • Webcasts
    • ETFs Future-Forward 2021: An iShares Investing Symposium
    • Three Themes for 2021: An iShares & MSCI Investing Symposium
  • Themes
    • AI ETFs
    • Blockchain ETFs
    • See all Thematic Investing ETF themes
    • ESG Investing
    • Marijuana ETFs
  • Videos & Podcasts
    • ETF 360 Video Series
    • ETF Trends on Videos
    • ETF Trends on Podcasts
    • ETF Prime Podcast
  • PRO
    • Pro Content
    • Pro Tools
    • Advanced
    • FAQ
    • Pricing
    • Free Sign Up
    • Login
  1. Disruptive Technology Channel
  2. The Pandemic Is Opening the Door for Genetic Testing
Disruptive Technology Channel
Share

The Pandemic Is Opening the Door for Genetic Testing

Tom LydonJun 02, 2021
2021-06-02

The COVID-19 pandemic accelerated adoption of an array of disruptive growth technologies, including e-commerce, fintech, and more.

Healthcare innovation is part of that trend, and the ARK Genomic Revolution Multi-Sector Fund (ARKG ) is an exchange traded fund for investors to consider as the pandemic compels healthcare professionals to explore new concepts in genetic testing.

Prior to the pandemic, many patients didn’t discuss genetics with primary care providers, but that landscape is changing.

“Propelled by the COVID-19 pandemic, we believe innovative virtual healthcare and genetic testing companies are poised to address these obstacles,” according to ARK Invest research. “Perhaps more importantly, these groups are highly incentivized to work together.”

ARKG's Genetics Testing Opportunities

When it comes to making genetics testing more accessible at the primary care provider level, some ARKG components are already making the necessary investments.

“Groups like Teladoc (TDOC), One Medical (ONEM), and Accolade (ACCD) have invested aggressively in virtual primary care services. One Medical’s ‘click-and-mortar’ platform spans both digital and in-person primary care and incorporates its own EHR system,” notes ARK Invest.

Teladoc is ARKG’s largest holding at just over 7% of the fund’s weight, as of June 1. Accolade and One Medical combine for 3.3% of the fund’s roster.

There are other avenues into the genetics testing realms. For example, some ARKG member firms are using AI to enhance genetics testing procedures and bring that concept to a wider audience of patients.

“Meanwhile, testing providers like Natera (NTRA), Invitae (NVTA), and Myriad Genetics (MYGN) have launched AI-enabled chatbots to facilitate genetic testing,” adds ARK. “With acquisitions of Clear Genetics and YouScript, for example, Invitae’s platform offers consent, pre- and post-test education, automated family history collection, results reporting, virtual genetic counseling, integration with electronic healthcare records like Epic and Cerner, CDST capabilities, and low-cost patient-pay options.”

Invitae accounts for 1.76% of ARKG’s weight. The overall genetics testing market is forecast to reach $21.26 billion by 2027, posting a compound annual growth rate of 10.1% from 2020 through 2027, according to Allied Market Research. Prenatal and predictive and pre-symptomatic testing are the largest segments in this arena.


Content continues below advertisement

ARKG 1 Year Performance

For more on disruptive technologies, visit our Disruptive Technology Channel.

Loading Articles...
Help & Info
  • Contact Us
  • About Us
  • Mission Statement
  • Press
Tools
  • ETF Screener
  • ETF Analyzer
  • Mutual Fund to ETF Converter
  • Head-To-Head ETF Comparison
  • ETF Country Exposure Tool
  • ETF Stock Exposure Tool
  • ETF Performance Visualizer
  • ETF Database Model Portfolios
  • ETF Database Realtime Ratings
  • ETF Database Pro
More Tools
  • ETF Launch Center
  • Financial Advisor & RIA Center
  • ETF Database RSS Feed
Explore ETFs
  • ETF News
  • ETF Picks of the Month
  • ETF Category Reports
  • Premium Articles
  • Alphabetical Listing of ETFs
  • Best ETFs
  • Browse ETFs by ETF Database Category
  • Browse ETFs by Index
  • Browse ETFs by Issuer
  • Compare ETFs
Legal
  • Terms of Use and Privacy Policy
  • © ETF Flows LLC
Follow ETF Database
Follow ETF Database

Advertisement

Is Your Portfolio Positioned With Enough Global Exposure?

Equity ETF Channel

Retirement Portfolio Redux: Is the 60%-40% Portfolio Dead?

Debbie CarlsonOct 22, 2020
2020-10-22

With the 10-year U.S. Treasury yield hovering below 1% and Federal Reserve Chairman Jerome Powell...

Equity ETF Channel

Portfolio Diversification Isn't Dead, It Was Just Sleeping

Debbie CarlsonOct 15, 2020
2020-10-15

Investors could be forgiven to think there was no reason to invest outside of the U.S. for the...

}
X